This trial is evaluating whether DREEM 2 Headband will improve 10 primary outcomes in patients with Dementia. Measurement will happen over the course of Week 12.
This trial requires 30 total participants across 3 different treatment groups
This trial involves 3 different treatments. DREEM 2 Headband is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"Age and gender influence the risk for AD. Approximately 80% of patients have Alzheimer's at onset, with about one-third presenting with mild cognitive impairment, and half having mild dementia; the prevalence of Alzheimer's disease increases rapidly with age and the disease continues to expand." - Anonymous Online Contributor
"Pharmacotherapy is the treatment of choice for most patients presenting with early onset AD. The most common medications used to treat patients with moderate-to-late onset AD vary with country. The most common medications used are antidepressants to treat depressive symptoms and sedatives for insomnia. Anticholinergics may also be used. Patients with very late onset AD commonly receive neuroleptic medications in order to control agitation, hallucinations or other behavioral disturbances. Older patients frequently present with severe cognitive deficits and are not likely to respond to medication. The optimal treatment strategy for patients with Alzheimer disease is not well understood, and many different medications can be used. However, several recent studies indicate some medications may be superior to others in the management of patients with AD." - Anonymous Online Contributor
"Alzheimer's disease (AD) is a progressive neurodegenerative disorder. It is characterized by abnormal accumulations of beta-amyloid (Aβ) in the brain and brain tissue, tau protein tangles, neurofibrillary tangles and senile plaques. The exact cause is unknown but is believed to disrupt signaling between neurons, thereby causing the death of nerve cells in memory areas. It is the sixth-leading cause of death in the United States and other developed nations." - Anonymous Online Contributor
"If someone has any of these symptoms it is important to find out what causes them as this is very important and helps treatment of the disease. Cognitive impairment is the most important criterion of alzheimers. Early and constant [dementia](https://www.withpower.com/clinical-trials/dementia) is a feature of most forms of Alzheimer
s. In an onset-of-dementia with age-changes setting of Alzheimer`s, the diagnosis of frontotemporal dementias may be appropriate with memory loss, language changes and behaviour that change with age and are progressive. If there are atypical features of progressive dementia of the Alzheimer's type, a diagnosis of the dementia with Lewy bodies variant is more appropriate so that treatment with Lewy bodies can be monitored appropriately." - Anonymous Online Contributor
"We hypothesize that an abnormal amyloidogenic precursor protein (APP) may trigger the disease and this is amplified in the presence of a genetic risk factor, such as APOE4." - Anonymous Online Contributor
"At present no treatments exist that improve or terminate the course of Alzheimer's disease, although this is one of the best researched and most severe debilitating diseases. The aim of this paper is to present a rationale for a cure based on the understanding of the pathological and biochemical cascade that promotes the pathological manifestations of Alzheimer's disease." - Anonymous Online Contributor
"The most common use of dreem 2 in combination was with cholinergic agents and the most common use of dreem 2 by itself was with aniridia. A greater number of the subjects were also prescribed cholinergic agents. A significant number of AAS users reported that dreem 2 is the only treatment type used in a majority of their use of AAS. This information may have an impact on the marketing of dreem 2, providing potential avenues to market additional products for use with AAS." - Anonymous Online Contributor
"Very few new drug treatments for AD have been reported in recent years. The development of new treatments will depend on improved understanding of the biology of AD and identification of new targets for therapeutic intervention." - Anonymous Online Contributor
"This case series demonstrates effectiveness of the use of a skull cap, when worn by a patient suffering from dementia, as an add-on to other therapeutic measures. A skull cap can be a simple, inexpensive or even free intervention, when patients are not satisfied with the management of their dementia with existing pharmacological treatments. The skull cap has been used in our institution for over a decade, and we are quite satisfied with our results, which are being disseminated in our community." - Anonymous Online Contributor
"A study from 2017 found that dementia could not be explained solely by cognitive changes. According to other studies, cognitive changes are observed in those with high risk for Alzheimer Disease before dementia begins, but other risk factors contribute to cognitive decline in those with no risk of dementia or mild cognitive impairment (mild cognitive deficits) before dementia begins. The authors propose that these two groups may have different brain processes that can impact cognition in different ways. You can find the most recent dementia clinical trials by using [Power](https://www.power." - Anonymous Online Contributor
"There have been many anecdotal claims about the headband, many unsupported and unsubstantiated by convincing empirical evidence. Although the headband may appear to be effective, the results on most reported trials are inconclusive and have low quality. This review demonstrates that there is no compelling evidence to support the effectiveness of the headband against the challenges associated with Alzheimer's disease." - Anonymous Online Contributor
"Altered brain development is present well before neurodegeneration is evident on imaging. Identifying the prevalence of early brain changes may lead to earlier detection of early-stage cases of AD. The data support further study of early brain changes in a population-based sample of young Americans as a means of screening for disease at-risk and as a target population for early intervention." - Anonymous Online Contributor